Skip to content

Study · Non-randomized trial · n = 10 · 2017

3 results

Tolerance Does Not Develop Toward Liraglutide's Glucose-Lowering Effect.

Sedman T, Vasar E, Volke V

The Journal of clinical endocrinology and metabolism1 Jul 2017Cited by 8 (Europe PMC)

PMID28379427 (opens in a new tab)DOI10.1210/jc.2017-00199 (opens in a new tab)PepBankPUB-28379427
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In healthy volunteers, liraglutide decreased glucose values during the graded glucose infusion test.

    In plain wordsIn healthy volunteers, liraglutide lowered blood glucose during a glucose infusion test.

    Peptide
    Liraglutide
    Outcome
    DecreaseGlucose during graded glucose infusion test
    Study

    n = 10

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.6 mg once daily · subcutaneous · 21 daysAs given in this study (human).

    Source sentences

    Summary
    Liraglutide clearly decreased the glucose values during the graded glucose infusion test
    1 context sentence
    Summary · context
    Ten healthy volunteers were treated with 0.6 mg liraglutide once daily subcutaneously for 21 days.
  2. 02HumanNon-randomized trialEfficacy outcome

    In healthy volunteers, liraglutide enhanced insulin secretion during the graded glucose infusion test.

    In plain wordsIn healthy volunteers, liraglutide strongly increased insulin release during a glucose infusion test.

    Peptide
    Liraglutide
    Outcome
    IncreaseInsulin secretion during graded glucose infusion test
    Study

    n = 10

    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    0.6 mg once daily · subcutaneous · 21 daysAs given in this study (human).

    Source sentences

    Summary
    robustly enhanced insulin secretion.
    1 context sentence
    Summary · context
    Ten healthy volunteers were treated with 0.6 mg liraglutide once daily subcutaneously for 21 days.
  3. 03HumanNon-randomized trialEfficacy outcome

    In healthy volunteers, chronic liraglutide was as effective as acute treatment for all parameters, so no tolerance to its glucose-lowering effect developed.

    In plain wordsIn healthy volunteers, three weeks of liraglutide worked as well as the first dose, with no loss of effect.

    Peptide
    Liraglutide
    Outcome
    No significant changeChronic versus acute glucose-lowering effect (tolerance)
    Study

    n = 10

    Comparator
    Acute liraglutide treatment
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.6 mg once daily · subcutaneous · 21 daysAs given in this study (human).

    Source sentences

    Summary
    For all parameters, chronic liraglutide was as effective as acute treatment in human subjects.
    1 context sentence
    Summary · context
    Ten healthy volunteers were treated with 0.6 mg liraglutide once daily subcutaneously for 21 days.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT02089256

Effect of Repeated Administration of Liraglutide on Insulinogenic Indices

University of Tartun = 10Jun 2014 to Mar 2015

Healthy

Trial pageClinicalTrials.govUpdated 1 Apr 2015

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.